Q (sonnet): Are TP53 mutations clinically actionable?

═ answer (success)
I can help you explore TP53 mutation data in cBioPortal, but I should clarify the scope of your question first.

**On clinical actionability:** This is a clinical/therapeutic interpretation question that falls outside what I can answer from cBioPortal data. cBioPortal reports genomic alteration data (frequencies, variant types, co-occurrence patterns) — it does not curate or provide clinical actionability tiers or treatment recommendations. Actionability assessments (e.g., OncoKB levels of evidence, FDA-approved therapies, clinical trial eligibility) come from specialized knowledgebases like [OncoKB](https://www.oncokb.org), not from the mutation frequency/clinical data tables I query.

Generally speaking (not from cBioPortal data, and not clinical advice): TP53 is one of the most commonly mutated genes across human cancers, but it is broadly considered difficult to target directly with approved therapies, unlike genes such as EGFR or BRAF where specific inhibitors exist. Whether a specific TP53 alteration in a specific tumor context is actionable is a question for a clinical oncologist or a curated resource like OncoKB — not something I can determine.

**What I *can* show you from cBioPortal:**
- How frequently TP53 is mutated in a specific cancer type or study
- Which TP53 variants/hotspots are observed
- Co-occurrence or mutual exclusivity with other genes
- OncoPrint views and mutation-type breakdowns

Would you like me to pull TP53 mutation frequency and variant data for a particular cancer type or study (e.g., TCGA PanCancer)? If so, let me know the cancer type of interest and I can generate the data plus a direct link to explore it further.

> "I can help you visualize the relevant data in cBioPortal, but this is for research purposes only. I cannot offer clinical advice or prognosis."